231085
Cilostamide
A cell-permeable selective inhibitor of cGMP-inhibited phosphodiesterase (PDE III; IC50 = 70 nM).
別名:
Cilostamide, N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide, OPC 3689
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C20H26N2O3
CAS番号:
分子量:
342.43
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
[nH]1c2c(cc[c]1=O)cc(cc2)OCCCC(=O)N(C3CCCCC3)C
InChI
1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23)
InChI key
UIAYVIIHMORPSJ-UHFFFAOYSA-N
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
関連するカテゴリー
General description
A cell-permeable selective inhibitor of cGMP-inhibited phosphodiesterase (PDE III; IC50 = 70 nM).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PDE 3
PDE 3
Product does not compete with ATP.
Reversible: no
Target IC50: 70 nM against PDE III
Preparation Note
Following reconstitution, refrigerate (4°C). Stock solutions are stable for up to 6 months at 4°C.
Other Notes
Verghese, M.W., et al. 1995. J. Pharmacol. Exp. Ther. 272, 1313.
Christensen, S.B., and Trophy, T.J. 1994. Ann. Rep. Med. Chem. 29, 185.
Tang, K.M., et al. 1994. Eur. J. Pharmacol. 268, 105.
Christensen, S.B., and Trophy, T.J. 1994. Ann. Rep. Med. Chem. 29, 185.
Tang, K.M., et al. 1994. Eur. J. Pharmacol. 268, 105.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
231085-MG: + 231085-10MG:
jan
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Natasja G J Costermans et al.
Journal of visualized experiments : JoVE, (172) (2021-07-06)
Events associated with oocyte nuclear maturation have been well described. However, much less is known about the molecular pathways and processes that take place in the cytoplasm in preparation for fertilization and acquisition of totipotency. During oocyte maturation, changes in
Chisato Kunitomi et al.
Development (Cambridge, England), 151(11) (2024-05-24)
The RNA-binding protein cytoplasmic polyadenylation element binding 1 (CPEB1) plays a fundamental role in regulating mRNA translation in oocytes. However, the specifics of how and which protein kinase cascades modulate CPEB1 activity are still controversial. Using genetic and pharmacological tools
Line M Grønning et al.
FEBS letters, 580(17), 4126-4130 (2006-07-11)
Overexpression of forkhead transcription factor FOXC2 in white adipose tissue (WAT) leads to a lean phenotype resistant to diet-induced obesity. This is due, in part, to enhanced catecholamine-induced cAMP-PKA signaling in FOXC2 transgenic mice. Here we show that rolipram treatment
Leen Vanhoutte et al.
Human reproduction (Oxford, England), 22(5), 1239-1246 (2007-02-17)
The use of hormones for controlled ovarian stimulation results in follicular heterogeneity, with oocytes at diverse stages of nuclear and cytoplasmic development. This study evaluated the impact of temporary nuclear arrest by a specific phosphodiesterase 3-inhibitor (PDE3-I), cilostamide, on nuclear
Xuan G Luong et al.
Nucleic acids research, 48(6), 3257-3276 (2020-01-24)
During oocyte maturation, changes in gene expression depend exclusively on translation and degradation of maternal mRNAs rather than transcription. Execution of this translation program is essential for assembling the molecular machinery required for meiotic progression, fertilization, and embryo development. With
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| 231085-10MGCN | 04055977217599 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）